David R Berk
Overview
Explore the profile of David R Berk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eichenfield L, Serrao R, Prajapati V, Browning J, Swanson L, Funk T, et al.
Pediatr Dermatol
. 2025 Feb;
PMID: 39980188
Background/objectives: Efficacy and safety of roflumilast cream 0.15% were demonstrated in patients aged ≥ 6 years with atopic dermatitis (AD) in two Phase 3 trials. This Phase 3 parallel-group, double-blind...
2.
Simpson E, Eichenfield L, Papp K, Forman S, Hebert A, Gonzalez M, et al.
Dermatitis
. 2025 Jan;
PMID: 39792455
Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials. Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.15% in...
3.
Draelos Z, Higham R, Osborne D, Seal M, Burnett P, Berk D
J Drugs Dermatol
. 2024 Oct;
23(10):834-840.
PMID: 39361692
Background: Inflammatory dermatologic conditions suitable for topical treatments benefit from a hydrating vehicle that improves the skin barrier without irritation. Objective: This research was designed to assess skin barrier effects...
4.
Simpson E, Eichenfield L, Alonso-Llamazares J, Draelos Z, Ferris L, Forman S, et al.
JAMA Dermatol
. 2024 Sep;
160(11):1161-1170.
PMID: 39292443
Importance: Safe, effective, and well-tolerated topical treatment options available for long-term use in patients with atopic dermatitis (AD) are limited and associated with low adherence rates. Objective: To evaluate efficacy...
5.
Gold L, Adam D, Albrecht L, Alonso-Llamazares J, Ferris L, Gooderham M, et al.
J Am Acad Dermatol
. 2024 Mar;
91(2):273-280.
PMID: 38556093
Background: Efficacy and/or safety profiles limit topical psoriasis treatments. Objective: Evaluate long-term effects of once-daily roflumilast cream 0.3% in patients with psoriasis. Methods: In this open-label phase 2 trial, adult...
6.
Blauvelt A, Draelos Z, Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, et al.
J Am Acad Dermatol
. 2024 Jan;
90(5):986-993.
PMID: 38253129
Background: The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. Objective: Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD). Methods:...
7.
Kircik L, Alonso-Llamazares J, Bhatia N, Bukhalo M, Devani A, Draelos Z, et al.
Br J Dermatol
. 2023 Jun;
189(4):392-399.
PMID: 37279795
Background: Scalp psoriasis affects most patients with psoriasis, but it can be difficult to treat. Objectives: To evaluate the efficacy and safety of once-daily roflumilast foam 0.3% on scalp and...
8.
Zirwas M, Draelos Z, DuBois J, Kircik L, Moore A, Gold L, et al.
JAMA Dermatol
. 2023 May;
159(6):613-620.
PMID: 37133856
Importance: Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety. Objective: To assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis...
9.
Draelos Z, Adam D, Hong H, Lebwohl M, Lynde C, Nahm W, et al.
Br J Dermatol
. 2023 Mar;
188(6):810-812.
PMID: 36890712
No abstract available.
10.
Thurston Jr A, Osborne D, Snyder S, Higham R, Burnett P, Berk D
Am J Clin Dermatol
. 2022 Nov;
24(2):315-324.
PMID: 36422852
Background: Most patients with chronic plaque psoriasis receive topical treatment; however, available options lack a balance of efficacy with long-term safety and tolerability. Roflumilast cream 0.3% is a highly potent...